AiM Medical Robotics, a leading developer of MRI-compatible intraoperative robotics for neurosurgery, announces the unveiling of a prototype of its industry-first robotics platform as well as the receipt of funding from the Sontag Innovation Fund, a wholly owned venture subsidiary of The Sontag Foundation, one of the largest private funders of brain cancer research in the United States.
The Sontag Innovation Fund invests in early stage and innovative technologies with the potential to drive cures and improve the quality of life or life expectancy for brain cancer patients. The investment comes subsequent to the close of AiM’s seed financing round, which was announced in March.
“The prototype is a testament to the progress that our company has made so far, bringing us closer to our goal of improving outcomes for patients undergoing neurosurgery and providing cost savings to hospitals by eliminating errors and reducing procedure times,” says Bob Cathcart, CEO of AiM. “The Sontag Foundation’s commitment to fund innovative advancements towards the treatment of brain tumors perfectly aligns with AiM’s core values, and we look forward to a fruitful collaboration.”
“Dr. Pilitsis, Prof. Fischer, and the AiM team are developing a groundbreaking and innovative MRI-compatible robotics platform that has the potential to impact the lives of patients across neurological disorders,” said Scott Davis, Ph.D., Senior Associate of the Sontag Innovation Fund. “We are encouraged by the team and this technology and hope the investment will attract additional external capital to improve the health status of brain cancer patients.”
